Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CNNRF CannaRoyalty: Exclusive Q&A with CEO Marc Lustig
Read about a unique business model in cannabis that will maximize shareholder value while limiting risk!
Q&A with CEO of CannaRoyalty (CNNRF), (CSE:CRZ), Marc Lustig
Q&A with Dr. Richard Kenney, new Medical Director of TPIV
http://microcapresearch.com/dr-richard-kenney/
$CNNRF - CannaRoyalty - Unique Business Model A Big Winner
CannaRoyalty invested a mere $850,000 into one cannabis-related asset less than 2 years ago. That asset is now valued at $7.1M
That's the beauty (and winning strategy) of the CNNRF business model.
More at:
CannaRoyalty Corp. (CNNRF): Unique Business Model Delivers $7.1M From $850,000 Cannabis Investment
Q&A with John Stewart
CEO of Emblem Pharmaceutical division
http://microcapresearch.com/emblem-2/
Also, latest Investor deck (April, 2017)
http://microcapresearch.com/wp-content/uploads/2017/04/EMC_Pres_FINAL_April-3.pdf
Q&A w CEO of Emblem Pharmaceuticals (EMMBF, EMC.V)
http://microcapresearch.com/emblem-2/
Thanks Dadx4, and others, for the positive comments.
Mark's responses were detailed, rational, and (imo) provide a good look at where SGLB will fit in the AM space.
With NASDAQ and financing behind them, it's time for the company to deliver the revenue growth we're looking for...and every indication points to that new reality.
$CNNRF / CannaRoyalty turned $850,000 investment into $7.1M
CannaRoyalty business model takes equity stakes in cannabis-related brands, technology, and patents.
They made an $850,000 investment in Resolve Digital health that's now valued at $7.1M with today's news:
http://finance.yahoo.com/news/cannaroyalty-announces-successful-completion-5-111704035.html
Potential for several of CannaRoyalty's assets to go public = blockbuster potential
Check out what CannaRoyalty owns:
RESEARCH: http://cannaroyalty.com/the-assets/research/
CONSUMER BRANDS: http://cannaroyalty.com/the-assets/consumer-brands/
DEVICES and IP: http://cannaroyalty.com/the-assets/devices-and-intellectual-property/
EARLY STAGE STRATEGIC INVESTMENTS: http://cannaroyalty.com/the-assets/strategic-investments/
Market cap just $100M, and just ONE of 23 assets now valued at $7.1M. Big upside potential here imo.
$MSRT expected to turn cash-flow positive very near term
Many good things going on with in MassRoots right now, some are discussed here:
http://microcapresearch.com/massroots-msrt-2/
MSRT just bounced off 200 dma and ready to roll!
$VUZI update
http://microcapresearch.com/vuzi-tpiv/
Up > 20% since recommendation and expecting much much higher :)
$TPIV Holding Live Webcast Today
https://finance.yahoo.com/news/tapimmune-host-inaugural-quarterly-business-141500895.html
$TPIV: TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer
http://finance.yahoo.com/news/tapimmune-announces-fully-funded-phase-131500409.html
Also, live webcast today at 4:30 pm ET
https://finance.yahoo.com/news/tapimmune-host-inaugural-quarterly-business-141500895.html
GE's Greg Morris Discusses the Formation of GE Additive
Engineering.com
http://www.engineering.com/3DPrinting/3DPrintingArticles/ArticleID/14434/GEs-Greg-Morris-Discusses-the-Formation-of-GE-Additive.aspx
Institutional participation in $VUZI increasing
https://fintel.io/sot/us/vuzi
Who'd have thought this just 3 months ago....
2017: SGLB's breakout year.
Looks like more $ coming from DoD (not pr'd by company that I know of)
"Part of the funding also will go to TapImmune, Inc., a biotech company in Jacksonville, to produce the clinical-grade vaccine. TapImmune, Inc., has licensed the new HER-2 vaccine from Mayo Clinic."
http://newsnetwork.mayoclinic.org/discussion/mayo-clinic-to-test-vaccine-designed-to-provide-immune-response-against-early-breast-lesions/
$TPIV - Immuno-Oncology Vaccines in Four Phase II trials
Partners with $AZN, Mayo Clinic, and received a $13.3 million grant fully funding Phase II trial of vaccine TPIV 200 in 280 patients with triple negative breast cancer being conducted at Mayo Clinic
Market cap $36M seems too low given cash balance and government funding imo.
Investor deck:
http://microcapresearch.com/wp-content/uploads/2017/03/TapImmune-Investor-Deck-1.05.16-FINAL-v4.pdf
$VUZI and $DRIO are on the move
Two of our picks for 2017, Vuzix Corporation (VUZI) and DarioHealth Corp (DRIO), are on the move.
Not much beyond what I posted.
Was told Morf3D has their hands full keeping up w demand from aerospace.
$SGLB - Nice close w more of them to come.
The "Fitbit of Diabetes Management" growing sales by 282%, record Q4 on tap
http://microcapresearch.com/dario-health-drio/
It used to be one of iHub's most popular boards back in the day...
Until everyone realized the stocks were all junk that is
M.S. Rupe is a subscriber that knows SGLB inside and out.
I asked him if he'd be interested in writing about SGLB and he agreed.
Hope to have a Q&A w Marc Cola out soon, but the timing is not mine to determine.
$DRIO: Q4 will be another record in top and bottom line growth
Launch in Germany, Android launch in US, well capitalized w $5.1 million raise, running on all cylinders and market cap $28M.
Patience will be rewarded- nothing moves a stock like rapid revenue growth.
$DRIO - DarioHealth the Fitbit of Diabetes w 282% Sales Growth
Record Q4 on tap
More @ http://microcapresearch.com/dario-health-drio/
"Could be the Tequila but I don't believe so."
HA!
http://giphy.com/gifs/x71L3BKRuio3S/html5
Volume suggests some institutional buying imo.
It could be all retail, but I doubt it.
SGLB was already reporting quarterly, so no difference in timing of filings.
Initial listing costs and annual fee are in this link:
(They're on the "Capital Markets" tier.
https://listingcenter.nasdaq.com/assets/initialguide.pdf
I wouldn't expect analyst coverage until they show real revenues, but since I think we're going to see that (finally), coverage might come by eoy- just guessing.
I think that the offering isn't the only cash infusion SGLB will be realizing near term.
Keep in mind SGLB only needs about $2.7M in sales to break even and I believe, although I can't prove it yet, that Sigma will be rolling in the $ soon.
That said, I would rather have seen a larger raise priced above $4.50, but it is what it is. Being on NASDAQ will definitely be a big help in awareness.
I have never been paid by any company or any person to post about SGLB. Ever.
I pounded the table (hard) in 2013 because I believed the company would show significant revenue growth by 2014-2015...something that obviously didn't happen. Bottom line is I'm a big proponent in the long term growth of 3D printing, and I believe Sigma Labs has a patented product to meet a very critical industry need, especially w regards to high value aerospace segment.
I'm pounding now because I believe that long-awaited revenue is at hand, and those taking part in the offering must believe it as well.
I'll try to find it.
I'm looking forward to a great year also! With NASDAQ uplisting, SGLB's story will get to a much broader audience of retail and institutional investors.
And with the cash infusion from the offering the lights not only are on, SGLB has gas in the tank to (finally) get the full commercialization going- which is exactly what I believe they'll do this year.
Exciting times!
...and this is why there's a market. Differences of opinion are settled by a 3rd party, that party being the market.
Nothing drives a stock like revenue growth.
I get that you don't expect to see it this year, and that's certainly understandable given SGLB's history. Only time (and real revenue) will tell and the market will adjust accordingly.
My "bet" is that this is (finally) the year SGLB investors have been looking for, based on the dd I've done. I haven't said that in a long time either. But there's too many irons in the fire now, and Morf3D is a big one IMO
Yep.
I think the writing was on the wall...but it took longer than I originally thought.
To be clear, I did more than a few Q&As... from management of SGLB, to Arcam, to ONVO, to Terry Wohlers, and Assistant Director of America Makes, Rob Gorham among others.
https://3dprintingstocks.com/interviews-with-ceos-and-industry-experts/
This isn't "promotion". It's getting to know the space you're investing in.
re: for potential investors or those not familiar - the link referenced is from the promotion of 2013, which can be considered a template for what you are seeing now.
Yes, and yes.
Based on sales.
re: Do you figure they will receive their approvals from Nasdaq soon and that institutional investors will be game at $5 or more for purchasing the blocks of shares on offer?
I mean 3D printing's revenue generation (as far as public companies are concerned) did not meet the hype surrounding the space during much of 2013-2014. SGLB certainly is included there.
What's different now? I've done what I guess is a deep dive into some of the companies (public and private) that SGLB is currently working with via some contacts I have. I know that Morf3D for example, can not keep up with the demand for parts in aerospace right now, which is why a deal with SGLB makes perfect sense.
As we all know, SGLB has always had top tier partners they've worked with for a few years now, and they've not been able to generate the kind of revenue to date to impress the market.
I believe (strongly), that this is about to change. Of course I have no "inside information" but I do have a network of contacts that I can glean a great deal of salient information from re: what's going on in the space in general and more specifically, re: Morf3D.
Bottom line is I pounded the table on this stock starting in early or mid 2013, sold the profits when revenue generation didn't meet my expectations, and I'm buying back now because there are many many irons in the fire and some are going to pan out.
Lastly, SGLB can break even with just about $2.7M in sales. My gut tells me they'll have that this year. I don't expect you to trust my gut of course, but I trust it :)
Bottom line is anyone can have an opinion on where SGLB is headed this year. Not many (or any?) can show that they correctly called for it to outperform all other 3D printing stocks in 2013. This is my belief based on my due diligence: By Q2 at the latest, SGLB will have announced more sales to be accounted by eoy than the company has had in its history, and SGLB will again be the best performing 3D printing stock of 2017.
Oh, expecting NASDAQ by Q3.
re: Can you elaborate on your statement? What is different this time? What is your time frame? What rate do you see sales increasing to create this fundamental strength?
LOL- I wish I had the power to move a stock that much!
As for promotion- I've never been paid a dime by SGLB, or any party in any connected by the company in any way.
But I did make a killing on the stock in 2013 and believe I will again in 2017.
There's a time to buy, a time to sell, and a time to buy back. Timing is everything, and this time the rise in SGLB will be due to fundamentals and not 3D printing hype.